Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
LSD, psilocybin, mescaline +4 moreLSD, psilocybin, mescaline, DMT, DOx series, escaline, proscaline show less
Allylescaline
4-allyloxy-3,5-dimethoxyphenethylamine
Allylescaline (4-allyloxy-3,5-dimethoxyphenethylamine) is a synthetic psychedelic of the phenethylamine class. It is a close structural relative of mescaline, roughly ten times more potent.[1] It activates serotonin receptors in the brain, disrupting sensory filtering and producing the visual and cognitive shifts characteristic of phenethylamine psychedelics.[2]
Allylescaline (4-allyloxy-3,5-dimethoxyphenethylamine) is an emerging synthetic psychedelic of the phenethylamine class. It is a mescaline structural analog of the scaline series, distinguished by roughly ten-fold greater potency.[1] Allylescaline is a presumed 5-HT₂A receptor agonist, producing its effects by disrupting cortical sensory filtering and increasing neural excitability.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
LSD, psilocybin, mescaline +4 moreLSD, psilocybin, mescaline, DMT, DOx series, escaline, proscaline show less
First synthesized by Otakar Leminger in 1972, allylescaline was described alongside four other novel phenethylamines in a single Czech-language paper.[1] Alexander Shulgin documented it as entry #2 in PiHKAL (1991), based on a handful of self-reports.[3] It reached European research chemical markets in 2013 and remains unscheduled in several jurisdictions.[4]
Subjective effects include color enhancement, rippling surfaces, stimulation, and heightened sociability.[3] The experience is clear-headed and warm — lighter in body load than Mescaline, with a bright, engaged mood at lower doses and more visual, introspective territory at higher ones. Insomnia, next-day cognitive fog, and perceptual unease are characteristic unwanted effects.[3]
Allylescaline does not produce physical dependence, and no toxic or lethal dose has been published.[5][2] The principal risks are psychological — anxiety, paranoia, and a duration long enough to become exhausting; MAOIs block the compound's breakdown, dramatically amplifying effects and raising blood pressure to dangerous levels. It is among the least-studied psychoactive phenethylamines — what is known rests on a handful of self-reports, with no clinical research.[6]
History[edit]
Discovery
Otakar Leminger, a Czechoslovakian industrial chemist, first synthesized allylescaline in 1972 and published his findings upon retirement in the Czech journal Chemický průmysl.[1] His paper described five novel phenethylamines; allylescaline was singled out as the most active.[6] His self-experiments at 20 mg documented vertigo, warm color perception, object plasticity, and colorful closed-eye imagery lasting beyond 12 hours.[3]
PiHKAL documentation
Leminger's work reached Alexander Shulgin through a researcher named Stanislov Wistupkin.[6] Shulgin documented allylescaline as entry #2 — code AL — in PiHKAL (1991), based on self-reports at 24 mg and 35 mg describing rapid onset, clear-headedness, and social fluidity.[3]
Research chemical era
Allylescaline appeared on the European research chemical market around 2013 and was notified to the EMCDDA.[4] In 2015, NMR analysis confirmed the structural identity of commercially sold samples.[7] No clinical or academic pharmacological research has followed.
The name "allylescaline" derives from its structural relationship to mescaline: the "escal-" root indicates the escaline scaffold, with "allyl-" specifying the 4-position ether group. Shulgin assigned it the two-letter code AL. The original Czech-language paper has never been found in English translation — all English-language knowledge of Leminger's work comes through secondary sources.[6][3]
Chemistry[edit]
Structural class
Allylescaline belongs to the scaline subclass of phenethylamines — a family of mescaline analogues that keep the 3,5-dimethoxy pattern while varying the 4-position ether group.[1] Its molecular formula is C₁₃H₁₉NO₃ (237.29 g/mol as free base), and the defining structural feature is an allyloxy group at the 4-position — a short carbon chain ending in a double bond.[8][9]
That double bond distinguishes allylescaline from the other scalines — escaline, proscaline, isoproscaline — which all carry saturated ether chains at the 4-position. Within the scaline family, larger 4-position substituents produce greater potency than mescaline.[1][10] The 3,5-methoxy groups flanking the ring are structurally critical — restricting their rotation eliminates activity entirely.[11]
Pharmacology[edit]
Mechanism of action
No binding data exist for allylescaline — all mechanistic statements are inferred from its structural class. Allylescaline is presumed to activate serotonin receptors on neurons in the prefrontal cortex,[2] following the pattern of mescaline, which is a full agonist at these same receptors.[11] This activation increases excitatory signaling in higher brain regions — the likely basis of the psychedelic effects.
Pharmacokinetics
Oral ingestion is the only documented route; no pharmacokinetic data exist for allylescaline in any species. The first controlled pharmacokinetic study of oral mescaline in humans was published only in 2025.[12] Liver enzymes — including CYP3A4 and CYP2D6 — are the primary metabolic pathway for structurally related phenethylamines.[13]
The allyloxy double bond may be converted into a reactive intermediate during breakdown — a potential concern unique to allylescaline among the scalines. No metabolic studies have been conducted, and no half-life or elimination data exist.
Neuroscience[edit]
Where it acts
Allylescaline is expected to act on the prefrontal cortex and associated brain networks.[2] Serotonin receptor activation disrupts the brain's sensory filtering — the process that normally limits which signals reach conscious awareness. More raw sensory data gets through, producing the loosened perception, heightened pattern recognition, and altered sense of self characteristic of psychedelic states.
Why it matters
One leading framework — the REBUS model — proposes that psychedelics reduce the brain's reliance on learned expectations, giving raw sensory input more influence over perception. Allylescaline's reported effects — color enhancement, surface breathing, object plasticity[1] — fit this pattern well. Whether allylescaline also promotes structural changes in neurons, as some psychedelics do, is unknown.
Whether allylescaline achieves sufficient receptor activation at its active doses to produce the full psychedelic response — and whether its roughly ten-fold potency advantage over mescaline reflects better receptor binding, improved absorption, or slower breakdown — has not been tested.
Subjective Effects[edit]
The allylescaline experience is dominated by a clear-headed, warm stimulation. Colors sharpen, surfaces seem to ripple, and the mood becomes bright and social. At higher doses the experience becomes more visual and introspective, but it retains a cognitive transparency that sets it apart from heavier classical psychedelics.
Within the scaline family, allylescaline sits above escaline and proscaline in potency and reportedly offers more cognitive clarity. Compared to mescaline, it shares the characteristic warmth and color enhancement but appears to lack the pronounced body load and nausea — though this comes from fewer than five documented exposures.
First synthesized by Otakar Leminger in 1972, allylescaline was one of five novel phenethylamines described in a single Czech-language paper.[1] Alexander Shulgin documented it as entry #2 in PiHKAL (1991), establishing the compound's active dose range from a handful of self-reports.[3] The compound appeared on European research chemical markets in 2013[4] and remains unscheduled in several major jurisdictions.
Subjective effects include color enhancement, surface-level visual distortions, stimulation, and enhanced sociability.[3] The experience is characterized by a clear-headed, warm quality at lower doses — a phenethylamine glow with more cognitive transparency than Mescaline and less somatic weight. Insomnia, next-day cognitive fog, and dose-dependent perceptual unease are characteristic unsought effects.[3]
Allylescaline is not expected to produce physical dependence,[2] and no toxic dose or adverse event case report has been published.[5] The principal risks are psychological — anxiety, paranoia, and perceptual disturbance scaling with dose — compounded by a prolonged duration that commits the user to an extended altered state. No binding data, pharmacokinetic studies, or clinical trials exist;[6] allylescaline remains one of the least characterized psychoactive phenethylamines in the literature.
History[edit]
Discovery
Allylescaline was first synthesized by Otakar Leminger, a Czechoslovakian industrial chemist, who published his findings upon retirement in a 1972 paper in the Czech journal Chemický průmysl.[1] The paper described five novel phenethylamines — allylescaline, proscaline, escaline, MAPEA, and MEPEA — with allylescaline singled out as the most active.[6] Leminger's self-experiments at 20 mg documented vertigo, warm color perception, object plasticity, and colorful closed-eye imagery lasting beyond 12 hours.[3]
PiHKAL documentation
Leminger's work reached Alexander Shulgin roughly a decade later through a researcher named Stanislov Wistupkin.[6] Shulgin included allylescaline as entry #2 (code AL) in PiHKAL (1991), documenting three qualitative self-reports at doses of 24 mg and 35 mg that described rapid onset, clear-headedness, and social fluidity, with a dissociative quality and next-day hangover at the upper end of the range.[3]
Research chemical era
Allylescaline appeared on the European research chemical market circa 2013 and was notified to the EMCDDA.[4] In 2015, Chapman and Avanes published NMR characterization of grey-market samples, confirming the structural identity of commercially circulating material.[7] No clinical or academic pharmacological research has followed.
The name "allylescaline" derives from its structural relationship to mescaline: the "escal-" root indicates the escaline (3,5-dimethoxy-4-alkoxyphenethylamine) scaffold, with "allyl-" specifying the allyl ether at the 4-position. Shulgin assigned it the two-letter code AL. The original Czech-language paper describing allylescaline is not indexed in any major database and has never been located in English translation — all English-language knowledge of Leminger's work is mediated through secondary sources.[6][3]
Chemistry[edit]
Structural class
Allylescaline belongs to the scaline subclass of substituted phenethylamines — mescaline analogues that retain the 3,5-dimethoxy substitution pattern while replacing mescaline's 4-methoxy group with a variable ether at the para position. The scaline series includes escaline (4-ethyloxy), proscaline (4-propyloxy), isoproscaline (4-isopropyloxy), and allylescaline (4-allyloxy).
The allyl group introduces a terminal alkene (C=C double bond) absent in the saturated-chain scalines. This increases lipophilicity and creates a potential metabolic vulnerability at the double bond — a feature unique to allylescaline among its series.
Molecular properties
| Molecular formula | C₁₃H₁₉NO₃ |
| Molecular weight | 237.29 g/mol (free base); 273.8 g/mol (HCl salt) |
The core structure is a phenethylamine backbone with methoxy groups at positions 3 and 5 and a prop-2-en-1-yloxy (allyloxy) group at position 4.[8][9] The allyloxy group's terminal alkene is the defining structural feature relative to other scalines.
Stereochemistry
Allylescaline is achiral. The molecule contains no stereogenic centers — the ethylamine side chain bears no α-substituent, and the allyloxy ether is symmetric about its attachment point. Unlike amphetamine-class phenethylamines, scaline-class compounds exist as single constitutional isomers without enantiomeric pairs.
Structure-activity relationships
Within the scaline series, increasing the size and lipophilicity of the 4-position substituent generally enhances potency relative to mescaline.[1] The 3,5-methoxy groups must remain conformationally mobile for receptor activation — restricting their rotation abolishes activity.[10] The 4-position tolerates structural variation, a feature predicted by mescaline analogue structure-activity data.[11]
The hydrochloride salt is a crystalline solid.[5] No melting point, formal solubility, or stability data have been published.
Pharmacology[edit]
Mechanism of action
No published binding data exist for allylescaline at any receptor. All mechanistic statements are inferred from its structural class.
As a 3,5-dimethoxy-4-substituted phenethylamine, allylescaline is presumed to act primarily as an agonist at serotonin 5-HT₂A receptors on neurons in the prefrontal cortex.[2] Activation of these receptors increases cortical glutamate release, amplifying excitatory signaling in higher brain regions.[2] Secondary activity at 5-HT₂C receptors is inferred from mescaline's pharmacology.
The parent compound mescaline functions as a full agonist at 5-HT₂A receptors.[10] The allyloxy substituent's greater lipophilicity compared to escaline's ethyloxy and proscaline's propyloxy groups may contribute to enhanced brain penetration or receptor affinity, but this remains untested.
Pharmacokinetics
No pharmacokinetic data exist for allylescaline in any species. All parameters below are inferred from mescaline and related compounds.
Oral administration is the sole documented route. Mescaline is well absorbed from the gut; the first controlled pharmacokinetic study of oral mescaline in humans was published in 2025.[12]
Dimethoxyphenethylamines are primarily broken down through oxidative deamination and liver enzyme-mediated demethylation. For structurally related compounds in the NBOMe series, CYP3A4 and CYP2D6 have been identified as the principal metabolic enzymes.[13] The allyloxy group introduces a metabolic vulnerability at its terminal double bond — liver enzymes may convert it to a reactive intermediate — but no metabolic studies have been conducted.
No elimination data (half-life, clearance, urinary recovery) have been published. The prolonged subjective duration may reflect slow breakdown, extended receptor binding, or both.
Neuroscience[edit]
Where it acts
As a presumed serotonin 2A receptor agonist, allylescaline is expected to act on the prefrontal cortex and associated networks.[2] Activation of serotonin receptors on cortical neurons disrupts the brain's sensory gating — the filtering process that normally limits which information reaches conscious awareness — while increasing communication between brain regions that do not ordinarily interact. These changes underlie the perceptual loosening, heightened pattern recognition, and altered sense of self characteristic of psychedelic states.
Why it matters
The REBUS (Relaxed Beliefs Under Psychedelics) model offers the most explanatory framework: psychedelics reduce the brain's reliance on learned expectations, allowing raw sensory data greater influence over perception. Allylescaline's reported effects — enhanced color, surface breathing, object plasticity[1] — are consistent with this relaxation of top-down processing. Serotonergic psychedelics also promote structural changes in neurons via growth factor signaling, a property termed psychoplastogenesis — whether allylescaline shares this property is unknown.
Several questions remain unresolved. Whether allylescaline achieves sufficient receptor occupancy at its active doses to trigger the full psychedelic response — and whether its roughly ten-fold potency advantage over mescaline reflects better receptor binding, improved absorption, or slower breakdown — has not been tested.
Subjective Effects[edit]
The allylescaline experience is defined by a clear-headed, stimulating warmth at lower doses that distinguishes it from the heavier body load of mescaline. At threshold and low doses the effect is predominantly social and communicative — enhanced verbal fluency and a bright, engaged mood — while higher doses tilt the balance toward introspective visual territory with surface breathing, object plasticity, and closed-eye imagery. Set and setting exert outsized influence on which mode predominates; published reports at identical doses diverge sharply on this axis.
Within the scaline series, allylescaline occupies a position of greater potency and cognitive clarity relative to escaline and proscaline. It shares the phenethylamine warmth and color enhancement of mescaline but reportedly lacks the pronounced nausea and bodily heaviness — though this observation derives from fewer than five documented exposures and awaits systematic confirmation.
Effect Grid
A moderate psychedelic state with emergent visual phenomena: color enhancement intensifies, surfaces may exhibit visual breathing, and closed-eye imagery becomes possible. Cognitive effects deepen — conceptual thinking, novelty enhancement, and pattern recognition enhancement become noticeable. Sociability and emotional enhancement are pronounced.
Stimulation is sustained throughout the 8–12 hour duration. Pupil dilation is evident. Mild muscle tension and occasional nausea may occur during the come-up phase. Heart rate may be slightly elevated.
Full functional impairment should be assumed. Sleep is impossible for 8+ hours following ingestion. Doses above 35 mg have no published human safety data.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Music enhancement · Environmental patterning · Visual breathing · Light sensitivity · Holotropic state · Perspective distortion · Symmetrical texture repetition · Tracers · Touch enhancement · Depth perception distortion · Visual morphing · Auditory enhancement · Peripheral vision distortion · Sound sensitivity · After-images · Visual diffraction · Visual melting · Visual haze / noise · Auditory distortion · Auditory misinterpretation · Peripheral misidentification · Spatial disorientation · Proprioceptive distortion · Visual acuity enhancement · Synesthesia · Vestibular distortion · Dreaming enhancement · Object transformations · Internal hallucinations · Visual recursion · External hallucinations · Object activation · Perspective hallucinations · Environmental orbism / cubism · Auditory hallucinations
Holotropic state · Perspective distortion · Symmetrical texture repetition · Tracers · Touch enhancement · Depth perception distortion · Visual morphing · Auditory enhancement · Peripheral vision distortion · Sound sensitivity · After-images · Visual diffraction · Visual melting · Visual haze / noise · Auditory distortion · Auditory misinterpretation · Peripheral misidentification · Spatial disorientation · Proprioceptive distortion · Visual acuity enhancement · Synesthesia · Vestibular distortion · Dreaming enhancement · Object transformations · Internal hallucinations · Visual recursion · External hallucinations · Object activation · Perspective hallucinations · Environmental orbism / cubism · Auditory hallucinations
Body high · Spontaneous body sensations · Muscle tension · Appetite suppression · Vibrations / buzzing · Tingling / electric sensations · Insomnia · Wakefulness · Restlessness · Excessive sweating · Dry mouth · Dizziness · Physical fatigue · Heart rate perception changes · Laughter fits · Tactile euphoria · Body schema distortion · Sexual arousal enhancement · Involuntary body movements · Bodily lightness · Abnormal heartbeat · Vomiting · Trembling
Appetite suppression · Vibrations / buzzing · Tingling / electric sensations · Insomnia · Wakefulness · Restlessness · Excessive sweating · Dry mouth · Dizziness · Physical fatigue · Heart rate perception changes · Laughter fits · Tactile euphoria · Body schema distortion · Sexual arousal enhancement · Involuntary body movements · Bodily lightness · Vomiting · Trembling
Openness enhancement · Cognitive euphoria · Immersion enhancement · Pattern recognition enhancement · Conceptual thinking · Cognitive flexibility · Thought connectivity · Increased nature relatedness · Thought loops · Multiple thought streams · Cognitive impairment · Focus suppression · Creativity enhancement · Memory suppression · Analysis enhancement · Thought acceleration · Thought disorganization · Confusion · Memory fragmentation · Humor enhancement · Cognitive fatigue · Synchronicity · Information processing enhancement · Information processing suppression · Cognitive dysphoria · Delusions
Pattern recognition enhancement · Conceptual thinking · Cognitive flexibility · Thought connectivity · Increased nature relatedness · Thought loops · Multiple thought streams · Cognitive impairment · Focus suppression · Creativity enhancement · Memory suppression · Analysis enhancement · Thought acceleration · Thought disorganization · Confusion · Memory fragmentation · Humor enhancement · Cognitive fatigue · Synchronicity · Information processing enhancement · Information processing suppression · Cognitive dysphoria
Simultaneous emotions · Anxiety · Catharsis
Sociability enhancement · Trust enhancement · Depersonalization · Flow state · Communication enhancement · Boundary dissolution · Ego dissolution · Cognitive disconnection · Identity alteration
Communication enhancement · Boundary dissolution · Ego dissolution · Cognitive disconnection · Identity alteration
Transpersonal visions · Entity contact
Recursive awareness
Timeline
First alerts emerge as subtle stimulation and slight mood elevation. A sense of mild alertness or warmth signals absorption without definitive psychedelic character.
Progressive intensification of stimulation with emerging color changes and increasing sociability. Physical energy builds; mild nausea possible during this phase.
Maximum intensity — visual phenomena (color enhancement, surface breathing, closed-eye imagery at higher doses), cognitive clarity or dissociative quality depending on dose, and social/communicative flow. Stimulation is prominent.
Gradual diminution of visual and cognitive effects over several hours. Stimulation persists longer than perceptual changes. Mood remains elevated but intensity recedes steadily.
Residual stimulation, potential insomnia, mild head congestion, and physical fatigue. Cognitive aftereffects may persist into the following day at moderate-to-high doses.
⚠ Avoid driving or operating machinery for at least 12 hours following ingestion, and longer if residual cognitive effects or fatigue are present.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 7 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- LSD · psilo · mesc
Toxicity
No lethal dose, toxic dose, or overdose case report has been published for allylescaline.[5] Its physiological and toxicological properties are explicitly unknown.
Class-level adverse effects
A systematic review of mescaline across 66 studies identified elevated blood pressure, headache, nausea, and vomiting as the most common adverse effects.[14] These are expected to apply to allylescaline given structural similarity.
The broader phenethylamine designer drug class has been associated with agitation, seizures, overheating, and — in fatal cases involving 2C-series compounds — excited delirium.[15] These fatalities involve the 2C series, not the scaline series, and are not directly comparable.
Reactive metabolite concern
Allylescaline's terminal double bond may be converted by liver enzymes into a reactive compound capable of damaging proteins. No published data confirm or exclude this pathway. This concern is unique to allylescaline among the scalines.safety citation needed
Psychological risks
No persistent psychological adverse effects specific to allylescaline have been documented. Class-level risks include[2]:
- Acute anxiety and paranoia, worsened by unfavorable set and setting
- Persistent visual disturbances following psychedelic use (sometimes called HPPD — hallucinogen persisting perception disorder)
- Triggering of psychotic episodes in people with personal or family history of psychotic disorders
- Prolonged psychological distress during the extended duration
Sleep difficulty requiring medication and next-day residual effects have been documented at 35 mg.[3]
Tolerance and dependence
Phenethylamine psychedelics do not produce physical dependence or addiction.[2] No compulsive use, withdrawal, or dose-escalation has been documented for allylescaline or any scaline-class compound.
Rapid tolerance develops after a single dose as serotonin receptors adapt,[16] and cross-tolerance with other serotonergic psychedelics — LSD, psilocybin, mescaline, and other scalines — is expected. One study found mescaline did not reduce cortical serotonin receptor density, unlike LSD and psilocybin,[17] suggesting the scaline class may build tolerance through different mechanisms.
Drug Interactions
No drug interaction data specific to allylescaline exist. All interactions below are class-level inferences.safety citation needed
- Monoamine oxidase inhibitors (MAOIs): monoamine oxidase is the primary enzyme that breaks down phenethylamines in the body. Blocking it — with antidepressants like phenelzine or tranylcypromine, or with natural compounds like harmine — dramatically increases the amount and duration of active compound. This raises blood pressure to dangerous levels and can trigger serotonin syndrome — a potentially life-threatening overheating and seizure response. Potentially life-threatening.safety citation needed
- Serotonergic drugs: SSRIs, SNRIs, and triptans raise background serotonin activity. Combined with a serotonin-activating psychedelic, they increase the risk of serotonin toxicity.[18] They may also paradoxically weaken psychedelic effects through chronic receptor adaptation.
- Lithium: Combining lithium with serotonergic psychedelics has been associated with seizures in the broader psychedelic literature.safety citation needed
- Stimulants: cocaine, amphetamines, and MDMA add cardiovascular risk — elevated blood pressure and rapid heart rate — on top of allylescaline's own stimulant effects.
- Cannabis: cannabis amplifies psychedelic effects unpredictably, increasing the risk of anxiety, paranoia, and psychotic symptoms — particularly at high doses or in inexperienced users.
Contraindications
6 knownNo substance-specific contraindication data exist. The following are inherited from the phenethylamine psychedelic class.safety citation needed
- Personal or family history of psychotic disorders — serotonin receptor activation may trigger or worsen psychosis
- Current MAOI therapy — risk of dangerous blood pressure elevation and serotonin toxicity
- Current lithium therapy — seizure risk
- Severe cardiovascular disease — phenethylamine psychedelics produce transient increases in blood pressure and heart rate[14]
- Pregnancy — no safety data; potential harm to the developing fetus is unknown
- Seizure disorders — seizure threshold may be lowered at high doses[15]
Harm Reduction[edit]
Forms & Identification
Allylescaline circulates as a white to off-white hydrochloride powder with no distinguishing visual features. Because it is active in the low milligram range, visual dose estimation is unreliable and dangerous. Weigh all material on a milligram-precision scale and verify with reagent testing.
The main identification risk is substitution: the powder is visually identical to dozens of other phenethylamine research chemicals, some with dramatically different potency profiles. Reagent testing confirms a phenethylamine is present but cannot distinguish between specific scalines or rule out adulterants. A drug checking service provides the highest confidence in identity and purity.
Guidelines
- Test all material with reagent kits and, where possible, a drug checking service before use
- Weigh doses on a milligram-precision balance (0.001 g); do not estimate by eye
- Consider volumetric dosing for additional precision at these low active doses
- Start at the low end of the documented range if inexperienced with this compound
- Have a sober, trusted companion present throughout
- Clear the full day and the following morning of obligations
- Keep water, light food, and comfort items accessible
- If the experience becomes distressing, move to a calm, familiar environment and focus on breathing
Set & Setting
The extended duration commits to a full day. Choose a physical environment that will remain safe and comfortable for at least 12 hours — with access to water, food, a quiet retreat space, and a bathroom. A trusted, sober companion is strongly recommended, particularly for first experiences or higher doses.
Psychological readiness matters as much as the physical setting. Fatigue, anxiety, unresolved emotional tension, and time pressure all increase the likelihood of a difficult experience. Begin only when rested, fed, hydrated, and free of obligations for the duration and the following morning.
Aftercare & integration. The day after an allylescaline experience may bring residual stimulation, difficulty sleeping, and mild cognitive fog — particularly at higher doses. Plan for a low-demand recovery day with adequate sleep, hydration, and nutrition.
Psychedelic experiences can surface unexpected emotional material. Journaling, conversation with a trusted person, or sessions with a psychedelic-informed therapist can help process and integrate insights. If distressing thoughts, perceptual changes, or mood disruption persist beyond a few days, seek professional support — early intervention improves outcomes.
Recovery & Support
Allylescaline does not produce physical dependence, and compulsive use has not been documented for the scaline class. Any psychoactive substance can, however, become part of avoidant or escapist behavioral patterns.
If psychedelic use is interfering with daily functioning, relationships, or wellbeing, support is available through psychedelic-informed therapists, harm reduction organizations, and peer support communities. The Fireside Project (62-FIRESIDE / 623-473-7433) offers free, confidential peer support during or after psychedelic experiences.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Most difficult psychedelic experiences are uncomfortable but not medically dangerous. Signs that require immediate help include: chest pain, seizure, loss of consciousness, extremely tachycardia that does not slow with rest, severe overheating, or behavior indicating risk of self-harm or harm to others.
Immediate steps:
- 1. Call emergency services if any of the above signs are present
- 2. Keep the person in a safe physical space away from hazards (heights, traffic, water)
- 3. Do not physically restrain unless there is immediate danger of self-harm
- 4. Speak calmly and reassuringly — remind them what they took, that the effects are temporary, and that help is coming
- 5. If unconscious but breathing, place in the recovery position (on their side, airway clear)
- 6. Do not induce vomiting
What to tell the dispatcher: Name the substance (allylescaline, a psychedelic phenethylamine), approximate amount taken, time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug-related emergency.
Legal Status[edit]
Allylescaline occupies an ambiguous legal position in most jurisdictions — explicitly controlled in some, unscheduled in others, and potentially reachable by structural analog laws in several more.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not specifically scheduled | Not listed in DEA schedules. The Federal Analogue Act (21 U.S.C. §813) is potentially applicable as a mescaline structural analogue if intended for human consumption. No case law specific to allylescaline.safety citation needed |
| United Kingdom | Prohibited | Covered by the Psychoactive Substances Act 2016; blanket prohibition on production, supply, and possession with intent to supply of any psychoactive substance not specifically exempted.[4] |
| Sweden | Controlled narcotic | Explicitly listed as a controlled narcotic substance; effective 26 January 2016.[4] |
| Switzerland | Controlled | Listed in Verzeichnis E of narcotics legislation.[4] |
| Germany | Controlled | Covered under analogue provisions of the Betäubungsmittelgesetz (BtMG) and Neue-psychoaktive-Stoffe-Gesetz (NpSG).citation needed |
| Japan | Controlled | Listed as a designated substance (shitei yakubutsu).[4] |
| Canada | Not controlled | Not listed in Schedules I–VI of the Controlled Drugs and Substances Act as of 2025.citation needed |
| Australia | Status unclear | Not specifically scheduled nationally; may fall under general analogue provisions in some state or territory jurisdictions.citation needed |
Analogue considerations
Allylescaline retains the complete 3,5-dimethoxyphenethylamine core of mescaline with only the 4-position ether modified — an unambiguous structural relationship. In jurisdictions employing structural analogue legislation, this may render allylescaline legally equivalent to mescaline when intended for human consumption. No case law or regulatory opinion specifically addressing allylescaline has been published.
Legal status changes frequently and varies by jurisdiction. This information reflects what was known at the time of writing and is not legal advice. Verify current status before acting on this information.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 7 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- LSD · psilo · mesc
Toxicity
No lethal dose, toxic dose, or overdose case report has been published for allylescaline. The physiological and toxicological properties of the compound are explicitly described as unknown.[5]
Class-level adverse effects
The most relevant safety data comes from a systematic review of mescaline across 66 studies, which identified elevated blood pressure, headache, nausea, and vomiting as the most commonly reported adverse effects.[14] These are expected to apply to allylescaline given structural similarity.
The broader phenethylamine designer drug class has been associated with agitation, aggression, elevated blood pressure, rapid heart rate, seizures, overheating, and — in fatal cases involving 2C-series compounds — excited delirium.[15] Five deaths attributed to 2C-series drugs appear in published literature; however, these involve the 2,5-dimethoxy substituted 2C series rather than the 3,5-dimethoxy scaline series and are not directly comparable.[15]
Reactive metabolite concern
The terminal double bond in allylescaline's allyloxy group may be converted by liver enzymes into a reactive epoxide intermediate capable of damaging proteins. No published data confirm or exclude this metabolic pathway. This concern is unique to allylescaline among the scalines and represents an uncharacterized risk.safety citation needed
Psychological risks
No persistent psychological adverse effects specific to allylescaline have been documented. Class-level risks for phenethylamine psychedelics include[2]:
- Acute anxiety and paranoia, dose-dependent and worsened by unfavorable set and setting
- Hallucinogen persisting perception disorder (HPPD) — persistent visual disturbances following psychedelic use
- Precipitation of psychotic episodes in individuals with personal or family history of psychotic disorders
- Prolonged psychological distress during the extended duration of effects
Sleep difficulty requiring medication and next-day residual effects have been documented at 35 mg.[3]
Tolerance and dependence
Phenethylamine psychedelics do not produce physical dependence or addiction.[2] No compulsive use, withdrawal, or dose-escalation behavior has been documented for allylescaline or any scaline-class compound.
Rapid tolerance (tachyphylaxis) develops after a single dose, consistent with 5-HT₂A receptor-mediated adaptation observed across serotonergic psychedelics.[16] A notable caveat: mescaline administered over multiple days did not reduce cortical serotonin receptor density in one study, unlike LSD and psilocybin.[17] This raises the possibility that tolerance mechanisms in the mescaline/scaline class may differ from those of indole psychedelics.
Cross-tolerance with other serotonergic psychedelics (LSD, psilocybin, mescaline, other scalines) is expected.[16]
Drug Interactions
No drug interaction data specific to allylescaline exist. All interactions below are class-level inferences.safety citation needed
- Monoamine oxidase inhibitors (MAOIs): monoamine oxidase is a primary breakdown pathway for phenethylamines. Irreversible MAOIs (phenelzine, tranylcypromine) and reversible MAOIs (moclobemide, harmine/harmaline) can dramatically increase the amount and duration of active compound by blocking its metabolism. This combination carries risk of dangerously elevated blood pressure and serotonin syndrome. Potentially life-threatening.safety citation needed
- Serotonergic drugs: SSRIs, SNRIs, and triptans increase background serotonin activity. Combined with a 5-HT₂A agonist, these agents increase the risk of serotonin toxicity.[18] SSRIs may paradoxically weaken psychedelic effects through chronic receptor adaptation.
- Lithium: lithium combined with serotonergic psychedelics has been associated with seizures in the broader psychedelic literature.safety citation needed
- Stimulants: cocaine, amphetamines, and MDMA present additive cardiovascular risk (elevated blood pressure, rapid heart rate) when combined with phenethylamine psychedelics.
- Cannabis: cannabis potentiates psychedelic effects unpredictably, increasing risk of anxiety, paranoia, and psychotic symptoms — particularly in inexperienced users or at high doses.
Contraindications
6 knownNo substance-specific contraindication data exist. The following are inherited from the phenethylamine psychedelic class:safety citation needed
- Personal or family history of psychotic disorders — 5-HT₂A agonism may trigger or worsen psychosis in vulnerable individuals
- Current MAOI therapy — risk of dangerously elevated blood pressure and serotonin toxicity
- Current lithium therapy — seizure risk
- Severe heart or cardiovascular disease — phenethylamine psychedelics produce transient increases in blood pressure and heart rate[14]
- Pregnancy — no safety data; potential for harm to the developing fetus is unknown
- Seizure disorders — seizure threshold may be lowered at high doses[15]
Harm Reduction[edit]
Forms & Identification
Allylescaline typically circulates as a white to off-white hydrochloride powder with no distinguishing visual features. Because it is active in the low milligram range, visual estimation of dose is unreliable and dangerous — material obtained from unregulated sources should be weighed on a milligram-precision scale and ideally verified with reagent testing.
The primary identification concern is substitution: the powder is visually indistinguishable from dozens of other phenethylamine research chemicals, some with dramatically different potency profiles. Reagent testing can confirm the presence of a phenethylamine but cannot distinguish between specific scalines or rule out adulterants. Sending a sample to a drug checking service provides the highest confidence in identity and purity.
Guidelines
- Test all material with reagent kits and, where possible, a drug checking service before use
- Weigh doses on a milligram-precision balance (0.001 g); do not estimate by eye
- Consider volumetric dosing for additional precision at these low active doses
- Start at the low end of the documented range if inexperienced with this compound
- Have a sober, trusted companion present throughout
- Clear the full day and the following morning of obligations
- Keep water, light food, and comfort items accessible
- If the experience becomes distressing, move to a calm, familiar environment and focus on breathing
Set & Setting
The extended duration means the user is committing to a full day. Choose a physical environment that will remain safe and comfortable for at least 12 hours, with access to water, food, a quiet retreat space, and a bathroom. A trusted, sober companion is strongly recommended, particularly for first experiences or higher doses.
Psychological readiness matters as much as environment. Fatigue, anxiety, unresolved emotional distress, and time pressure all increase the likelihood of a difficult experience. Begin only when rested, fed, hydrated, and free of obligations for the duration and the following morning.
Aftercare & integration. The day following an allylescaline experience may include residual stimulation, difficulty sleeping, and mild cognitive fog — particularly at higher doses. Plan for a low-demand recovery day with adequate sleep, hydration, and nutrition.
Psychedelic experiences can surface unexpected emotional material. Journaling, conversation with a trusted person, or sessions with a psychedelic-informed therapist can help process and integrate insights. If distressing thoughts, perceptual changes, or mood disruption persist beyond a few days, seek professional support — early intervention improves outcomes.
Recovery & Support
Allylescaline does not produce physical dependence, and compulsive use patterns have not been documented for the scaline class. However, any psychoactive substance can become part of avoidant or escapist behavioral patterns.
If psychedelic use is interfering with daily functioning, relationships, or wellbeing, support is available through psychedelic-informed therapists, harm reduction organizations, and peer support communities. The Fireside Project (62-FIRESIDE / 623-473-7433) offers free, confidential peer support for people during or after psychedelic experiences.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Most difficult psychedelic experiences are uncomfortable but not medically dangerous. Signs that require immediate help include: chest pain, seizure, loss of consciousness, extremely tachycardia that does not slow with rest, severe overheating (skin hot to the touch), or behavior indicating risk of self-harm or harm to others.
Immediate steps:
- 1. Call emergency services if any of the above signs are present
- 2. Keep the person in a safe physical space away from hazards (heights, traffic, water)
- 3. Do not physically restrain unless there is immediate danger of self-harm
- 4. Speak calmly and reassuringly — remind them what they took, that the effects are temporary, and that help is coming
- 5. If unconscious but breathing, place in the recovery position (on their side, airway clear)
- 6. Do not induce vomiting
What to tell the dispatcher: Name the substance (allylescaline, a psychedelic phenethylamine), approximate amount taken, time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug-related emergency.
Legal Status[edit]
Allylescaline occupies an ambiguous legal position in most jurisdictions. It is not specifically scheduled under United States federal law or in several other major markets, but falls within the scope of blanket psychoactive substance legislation in the United Kingdom and structural analog provisions in multiple European countries. Its structural relationship to mescaline creates potential liability under analogue acts even where not explicitly named.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not specifically scheduled | Not listed in DEA schedules. The Federal Analogue Act (21 U.S.C. §813) is potentially applicable as a mescaline structural analogue if intended for human consumption. No case law specific to allylescaline.safety citation needed |
| United Kingdom | Prohibited | Covered by the Psychoactive Substances Act 2016; blanket prohibition on production, supply, and possession with intent to supply of any psychoactive substance not specifically exempted.[4] |
| Sweden | Controlled narcotic | Explicitly listed as a controlled narcotic substance; effective 26 January 2016.[4] |
| Switzerland | Controlled | Listed in Verzeichnis E of narcotics legislation.[4] |
| Germany | Controlled | Covered under analogue provisions of the Betäubungsmittelgesetz (BtMG) and Neue-psychoaktive-Stoffe-Gesetz (NpSG).citation needed |
| Japan | Controlled | Listed as a designated substance (shitei yakubutsu).[4] |
| Canada | Not controlled | Not listed in Schedules I–VI of the Controlled Drugs and Substances Act as of 2025.citation needed |
| Australia | Status unclear | Not specifically scheduled nationally; may fall under general analogue provisions in some state or territory jurisdictions.citation needed |
Analogue considerations
Allylescaline retains the complete 3,5-dimethoxyphenethylamine core of mescaline with only the 4-position ether modified — an unambiguous structural relationship. In jurisdictions employing structural analogue legislation, this relationship may render allylescaline legally equivalent to mescaline when intended for human consumption. No published legal case or regulatory opinion specifically addressing allylescaline under analogue provisions has been identified.
Frequently asked questions
How long does Allylescaline last?
Total duration by route of administration — Oral: 8 – 12 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for Allylescaline?
Psychedex publishes a dosage table for Allylescaline on this page covering these routes of administration: oral. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with Allylescaline?
The highest-severity documented interactions for Allylescaline: MAOIs (Lethal), Buspirone (Dangerous), Dopamine agonists (Dangerous), GHB, Baclofen (Dangerous), GHB, GBL (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is Allylescaline addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for Allylescaline: tolerance builds rapid; full reset takes 7 days; cross-tolerance develops with LSD, psilocybin, mescaline, DMT, DOx series, escaline, proscaline. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
references
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]